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Summary HMFGI tumour associated monoclonal antibody IgGl and F(ab')2 fragments were radiolabelled
with indium-111 and used to study patients with breast cancer. In vitro and in vivo stability of the
radiolabelled antibodies was shown to be satisfactory. Thirty patients with primary breast cancer underwent
tumour resection and quantitative evaluation of the radioactivity in the tumour and normal tissues following
administration of specific and non-specific antibodies. The mean tumour uptake of HMFG1 F(ab')2
fragments at 24h was significantly higher (P<0.05) than the intact IgG but at 48h there was no difference.
The mean tumour uptake with the specific antibody was higher than the non-specific antibody of the same
subclass (P<0.05). Lymph node metastases showed higher antibody uptake than the corresponding primary
tumours (P<0.05). Fifteen patients with primary or metastatic breast cancer were investigated by external
body scintigraphy using HMFG1 F(ab')2 fragments. Successful localisation was observed in approximately
50% of the primary and metastatic lesions with no false positive results. All the patients had observable
concentration of "'1In in the liver (20% of the injected dose), the kidneys and the spleen. Following i.v.
administration, F(ab')2 fragments cleared from the blood more rapidly than the intact IgG. We conclude that
HMFG1 F(ab')2 fragments can localise specifically and faster than intact IgG in breast cancer but the
sensitivity of the radioimmunoscintigraphy is relatively low. This method needs further improvement before
becoming clinically useful for detecting and staging breast cancer.
Radiolabelled monoclonal antibodies raised against human
tumour associated antigens have been shown to localise
preferentially to tumours, both clinically and in experimental
animals (Mach et al., 1981; Epenetos et al., 1982; Farrands
et al., 1982; Granowska et al., 1986). Several investigators
have reported successful radioimmunolocalisation of breast
cancer (Colcher et al., 1983; Rainsbury, 1984; Kalofonos et
al., 1988b), but limitations of this approach are the low
absolute amount of antibody reaching the target (Epenetos
et al., 1986), the heterogeneity of antigenic expression in
tumour cells affecting antibody binding (Buchegger et al.,
1983) and the persistence of high levels of blood pool
radioactivity which makes tumour radioimmunodetection
difficult. Several methods have been reported to reduce the
blood pool activity. Begent et al. (1982) reported that
liposomally entrapped second antibody could be used to
improve tumour to blood ratios 10-fold in comparison to the
primary antibody alone. A second alternative is the use of
antibody fragments, enhancing the rate of radioactive
antibody removal from the blood so tumour could be
visualised earlier (Wahl et al., 1983; Khaw et al., 1984).
In this study we report our experience using 1"1In-labelled
F(ab')2 fragments as well as intact HMFG1 monoclonal
antibody in patients with breast cancer. The aim of this
study was to investigate kinetics, localising efficiency and
specificity of HMFG1 F(ab')2 fragments compared to intact
monoclonal antibody.
Patients, materials and methods
Patients
Two groups of patients were studied. The first consisted of
15 patients with primary and/or metastatic breast cancer,
who were studied by external body scintigraphy. The
patients' ages ranged from 38 to 72 years (mean 53). All the
patients received 1 mCi of "11In-labelled HMFG1 F(ab')2
fragments as an i.v. bolus over 1 min.
The second group consisted of 30 patients with primary
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breast cancer who underwent tumour resection 24 or 48h
following administration of specific or non-specific
monoclonal antibody. Quantitative evaluation of the radio-
activity in primary tumour and normal tissue specimens was
possible in these patients. The patients' ages ranged from 43
to 74 years (mean 60). Each patient received an i.v. bolus
injection of 0.5mCi of "'1In-labelled antibody.
The average amount of injected protein per patient was
250 ig (range 200-300 ug). All patients gave their written
informed consent before entering this study. They were skin
tested for hypersensitivity to mouse immunoglobulin. No
reactions were detected.
Monoclonal antibodies
HMFGJ Monoclonal antibody HMFG1 (Taylor-
Papadimitriou et al., 1981), is a murine IgGI directed
against a mucin molecule which is strongly expressed in
lactating breast as well as in a range of neoplasms of
epithelial origin such as breast, ovarian, gastrointestinal and
non-small cell lung cancer (Arklie et al., 1981). It also reacts
weakly with normal non-lactating breast and other normal
epithelial tissues. It is, therefore, not tumour-specific but it
can be described as a tumour-associated antibody. Purity of
the antibody was confirmed by isoelectric focusing (Awdeh
et al., 1968) and by polyacrylamide gel electrophoresis
(Laemmli, 1976). F(ab')2 fragments were produced by pepsin
digestion (Nisonoff et al., 1960) as described elsewhere
(Kalofonos et al., 1988a).
4C4 The monoclonal antibody 4C4 (Boniolo et al., 1982) is
a mouse IgGI directed against the hepatitis B surface
antigen. This antibody does not react with neoplasms of
epithelial origin such as breast cancer, or with any other
human tissues and was used as a negative control. F(ab')2
fragments of the 4C4 monoclonal antibody were kindly
provided by Sorin Biomedica (Saluggia, Italy).
Radiolabelling
Monoclonal antibodies were conjugated with DTPA
(diethylene triamino pentaacetic acid) using the cyclic-
anhydride form (Sigma) followed by radiolabelling with
11'In (molarity 0.04M, carrier-free, Amersham Int., UK) as
described by Hnatowich et al. (1983). The labelled antibody
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was separated from free IIIIn using gel filtration
(Sephadex G50). Antibody-DTPA conjugate before and
after labelling with indium was assessed for immuno-
reactivity by enzyme-linked immunosorbant assay (ELISA)
with delipidated milk fat globule protein acting as target for
the antibody, fixed on 96-well plastic plates (Epenetos et al.,
1986).
Immunohistology
After the tissues were counted, they were fixed in formalin,
embedded in paraffin and sectioned. The sections were
stained by an indirect two-stage immunoperoxidase
procedure. The concentration of the antibody was
0pgml-1. The sections were scored on the basis of the
percentage of cells stained. Positive tissues were scored when
50% or more of the tumour cells were stained.
Biodistribution studies
Tumour and normal tissues were removed at operation 24 or
48h after antibody administration. All the tissues removed at
operation were labelled according to the anatomical location,
and two representative specimens of each were immediately
weighed and counted in a gamma-counter against a standard
of the injectate, in order to establish the percentage of
injected dose per gram of tissue. Tumour and normal tissue
were classified as such only after histological examination.
Biopsies from necrotic areas were excluded from the
calculation.
Kinetic studies
Blood samples were taken at various intervals and urine was
collected for 5 days following the administration of the
antibody. Aliquots of the plasma and urine were counted in
a gamma-counter along with a standard of the injectate for
clearance studies.
Blood in heparinised tubes was centrifuged and the pellet
was washed twice in order to quantitate the radioactivity in
the pellet and the supernatant. Protein bound indium in the
plasma was quantitated by chromatography (Sephadex G50).
In vitro and in vivo stability of the indium-labelled antibodies
was assessed by SDS-polyacrylamide gel electrophoresis and
autoradiography as described elsewhere (Kalofonos et al.,
1988a).
Imaging studies
Antibody scans were generated in 15 patients with primary
or metastatic breast cancer, using a 40 cm field-of-view
gamma-camera with a medium energy collimator. Imaging
studies were carried out on at least three points in every
patient. Anterior and posterior whole body scans as well as
spot views were obtained. The relative percentage of activity
in the liver was calculated from the whole body scans by
dividing the geometric mean of the counts in the liver by the
geometric mean of the counts in the whole body.
Results
Radiolabelling
Monoclonal antibodies were conjugated with DTPA and
radiolabelled with "1'In resulting in approximately one
molecule of indium being attached onto one molecule of
antibody as described by Hnatowich et al. (1983). Labelling
efficiencies of 85-90% were achieved. Specific activity was in
the range of 3-5mCimg-1. No significant loss of the
immunoreactivity of the F(ab')2 fragments was found in
comparison with the intact IgG, and no significant loss was
found before and after DTPA coupling and radiolabelling.
Immunohistology
HMFGI F(ab')2 fragments and intact IgG were positive in
indirect immunoperoxidase reactions against all breast tissues
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Figure 1 Biodistribution of administered antibodies in breast
cancer patients. Percentage of injected dose (x 10 -3) of
administered antibody per gram of tumour, at 24 and 48 hours.
and 4C4 F(ab')2 fragments were negative against all breast
tissues.
Biodistribution study
Table I summarises the biodistribution of indium labelled
antibodies in breast cancer patients. The mean tumour
uptake with HMFG1 F(ab')2 fragments at 24h was
5.8 x 10-3% of injected dose per gram of tissue (Figure 1).
This was significantly higher than whole IgG,
2.9 x 10-3% IDg-1 (P<0.01) and non-specific antibody
1.7x 10-3%IDg-1 (P<0.05). At 48h there was no
significant difference between F(ab')2 fragments
(5.9 x 10-3% IDg-1) and intact IgG (6.9 x 10-3% IDg-1),
but both were higher than the non-specific antibody uptake
1.6 x 10-3% IDg-1 (P<0.05). Lymph node metastases,
interestingly, showed higher antibody uptake than the
correspondingly primary tumours (Table I) (P<0.05).
However, although lymph nodes with tumour infiltration
showed higher antibody uptake than normal lymph nodes
the difference was not statistically significant.
Kinetic studies
Blood clearance was identical for both HMFG1 and 4C4
F(ab')2 fragments. This was biphasic with a mean half-life of
the first component T112a=2.5+ 1.3 h and of the second
component Tl/2b=48+4.5h. The HMFG1 intact antibody
was cleared from the blood more slowly with T1/2a=24+2.8
and T112b=58+3.8h (Figure 2). The cumulative urinary
excretion of the indium label over 5 days was 10.6+2.6 and
9.8+2.8% of the injected dose in the patients studied with
Table I Biodistribution of I'1'n labelled HMFG1 intact and
F(ab')2 as well as 4C4 F(ab')2 fragments in breast cancer patients
(% injected dose g-X10-3 (mean +s.d.)) at 24 and 48h after
injection
HMFGJ HMFGJ-F(ab')2 4C4-F(ab')2
24h n=6 n=7 n=4
Blood 14.0+2.5 9.0+2.1 8.8+2.2
Tumour 2.9+0.5 5.8+0.7 1.7+0.6
Normal breast 1.6+0.4 1.8+0.3 1.4+0.2
Lymph node (tumour) 5.8+1.2 9.1+1.8 4.4+1.3
Lymph node (normal) 5.3+1.8 6.1+1.2 4.9+1.4
Fat 0.5+0.1 0.4+0.2 0.4+0.2
Skin 1.8+0.3 1.4+0.1 0.4+0.3
48h n=5 n=5 n=3
Blood 10.1+1.4 6.3+1.0 6.0+0.9
Tumour 6.9+0.9 5.9+0.8 1.6+0.6
Normal breast 1.7+0.3 0.8+0.2 0.9+0.3
Lymph node (tumour) 8.6+1.4 8.8 + 1.7
Lymph node (normal) 7.8 + 1.7 7.6+2.1
Fat 0.4+0.1 0.5+0.2 0.3+0.2
Skin 1.7+0.3 1.7+0.3 0.6+0.3
Numbers indicate % injected dose g-1 x 10-3 (mean+s.d.); n,
number of patients.
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Figure 2 Half-life of the radiolabelled HMFGI intact IgG and
F(ab')2 fragments in the blood.
F(ab')2 fragments and the intact antibody respectively. In all
the patients studied, the majority of the radioactivity (95%)
was associated with the plasma rather than the blood cells.
The mean percentage of the non-protein-bound indium in
the serum samples of the patients studied with HMFG1
F(ab')2 fragments was 3.64+0.86, 2.74+0.64 and 2.68 +0.88%
and in the patients studied with the HMFG1 intact antibody
was 3.57+1.16, 2.62+0.26 and 2.46+1.22% at 10min, 24h
and 48 h respectively. In vitro and in vivo stability of the
radiolabelled antibody was shown to be satisfactory and
there was- no evidence of significant aggregate formation
immediately after radiolabelling, nor in patient serum
samples after antibody administration as assessed by SDS-
polyacrylamide gel electrophoresis (PAGE) and autoradio-
graphy. PAGE showed that most of the radioactivity in the
plasma was associated with the monoclonal antibodies.
Imaging studies
Table II summarises the imaging results. Among 15 patients
with breast cancer investigated with indium-111-labelled
HMFG1 F(ab')2 fragments by external body scintigraphy,
we observed successful localisation in three out of seven
patients with primary breast cancer (Figure 3), in four out of
six patients with bone metastases, in two out of four with
skin metastases, in one out of two with lymph node
infiltration and in one out of two with liver metastases. The
gamma-camera images showed considerable uptake of radio-
activity by liver. There was also significant uptake by spleen
and kidneys. The relative fraction of the injected
radioactivity in the liver over 4 days remained constant,
which was estimated to be approximately 20% of the
administered dose.
Discussion
This study shows that the amount of "11In-labelled F(ab')2
fragments and intact HMFG1 monoclonal antibody reaching
target tissues after i.v. administration is relatively small.
However, it clearly demonstrates the ability of this antibody
to bind specifically to breast cancer lesions resulting in
successful immunolocalisation of approximately 50% of
cancer lesions.
One objective of this study was to assess the localising
Table II Antibody guided tumour detection with HMFGl-F(ab')2
fragments
Scans
Tumour Patients Positive Negative
Primary breast cancer 7 3 4
Lymph node metastases 2 1 1
Bone metastases 6 4 2
Skin metastases 4 2 2
Liver metastases 2 1 1
Figure 3 Antibody scan (lateral view) taken 72h after
administration of ll In-HMFGl-F(ab')2 fragments showing
tumour localisation in primary breast cancer (arrow P) and
axillary lymph node metastasis (arrow M).
effectiveness of I''In-labelled HMFG1 F(ab')2 fragments for
imaging in patients presenting with measurable disease, and
to compare this with the distribution of the disease as
determined by conventional methods. The results of our
studies show high specificity but low overall sensitivity. We
have shown no false positive localisation in 15 patients
studied. However, this technique suffers from an inability to
detect all known tumour sites. Epenetos et al. (1982), using
'23I-labelled intact HMFG1 and HMFG2 monoclonal
antibodies, studied six breast cancer patients. They observed
successful immunolocalisation in most of primary and
metastatic lesions but the number of patients studied with
each antibody was small. Rainsbury (1984), working with
another antibody (LCR-LON-M8), also directed against a
component of human milk fat globule and radiolabelled with
11lIn, demonstrated successful localisation in breast cancer
patients with bone metastases, but not in primary tumours
and the soft tissue metastases. In this current study we have
demonstrated successful localisation in primary tumours,
skeletal metastases and soft tissue metastases. This could be
explained by the faster clearance of blood pool radioactivity
along with faster tumour accretion after administration of
the F(ab')2 fragments. These findings favour the use of
F(ab')2 fragments for tumour radioimmunolocalisation and
are in agreement with our previous experience (Kalofonos et
al., 1988a) and the experience of others (Wahl et al., 1983;
Buraggi et al., 1985; Munz et al., 1986; Chatal et al., 1987).
Bone metastases were detected in a higher percentage (67%)
than the primary tumour (43%) or metastases in other
organs (50%) possibly due to the easier access of the
antibody to bone metastases through the rich medullary
blood supply.
In this study we observed significant non-specific
concentration of the 11'In in the liver, the spleen and the
kidneys. The accumulation of 111In in the kidneys with the
F(ab')2 fragments may be due to antibody catabolism
(Covell et al., 1986), active filtration (Khaw et al., 1984) and
exchange of 111In into ion-binding proteins within this
organ. Accumulation of 111In by the liver is not well
understood and could be a result of antibody catabolism and
exchange with iron-binding protein (Sands & Jones, 1987).
Most of the previous clinical trials using radiolabelled
monoclonal antibodies have relied solely on scans to
determine the accuracy of tumour binding by the
monoclonal antibody. In only a few trials have actual
tumour biopsy material been obtained for direct analysis of
monoclonal antibody delivery (Epenetos et al., 1986; Esteban
et al., 1987; Ward et al., 1987). In this study it became
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obvious that antibody localisation to the target was relatively
small. However, we observed significantly higher specific
antibody uptake than the irrelevant antibody by primary
breast tumours. There are different factors which could
account for the low accessibility of monoclonal antibodies in
the tumours including the lack of vascularity as well as the
amount and the type of interstitial stroma (Sands et al.,
1988; Jain, 1987). Breast cancer has a dense stromal
component which may inhibit the accessibility of the
antibody to reach all the antigen expressing tumour cells in
different areas of the tumour. Another important
observation in this study was that the F(ab')2 fragments
accumulated in the tumour faster, with maximum uptake
being achieved as early as 24h, compared to the intact
antibody where it was gradually increased and equivalent
uptake achieved at 48h. F(ab')2 fragments with molecular
weight lower than intact IgG and comparable immuno-
reactivity are cleared faster from the vascular moving to the
extravascular compartment, resulting in an increase in
tumour to background ratio.
In conclusion, this study demonstrates that "'In-labelled
HMFG1 F(ab')2 fragments can specifically localise breast
cancer lesions, but results obtained so far are inferior to
conventional radiology such as isotope bone scanning.
F(ab')2 fragments localise faster in the tumour than the
intact antibody and are cleared faster from the blood pool,
favouring their use for in vivo tumour localisation. However,
this study also illustrates the relatively low antibody uptake
of both IgG and F(ab')2 fragments by breast cancer. This
method needs further improvement before becoming useful
in clinical practice.
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